DK1603573T3 - Anvendelse af dipyridamol i kombination med acetylsalicylsyre og en angiotensin II-antagonist til forebyggelse af slagtilfælde - Google Patents

Anvendelse af dipyridamol i kombination med acetylsalicylsyre og en angiotensin II-antagonist til forebyggelse af slagtilfælde

Info

Publication number
DK1603573T3
DK1603573T3 DK04709596T DK04709596T DK1603573T3 DK 1603573 T3 DK1603573 T3 DK 1603573T3 DK 04709596 T DK04709596 T DK 04709596T DK 04709596 T DK04709596 T DK 04709596T DK 1603573 T3 DK1603573 T3 DK 1603573T3
Authority
DK
Denmark
Prior art keywords
dipyridamole
angiotensin
antagonist
combination
acetylsalicylic acid
Prior art date
Application number
DK04709596T
Other languages
Danish (da)
English (en)
Inventor
James C Gilbert
Axel Riedel
Lutz Hilbrich
David Michael Humphreys
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32870338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1603573(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK1603573T3 publication Critical patent/DK1603573T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04709596T 2003-02-13 2004-02-10 Anvendelse af dipyridamol i kombination med acetylsalicylsyre og en angiotensin II-antagonist til forebyggelse af slagtilfælde DK1603573T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10306179A DE10306179A1 (de) 2003-02-13 2003-02-13 Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
EP03018212 2003-08-08
PCT/EP2004/001208 WO2004071385A2 (en) 2003-02-13 2004-02-10 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention

Publications (1)

Publication Number Publication Date
DK1603573T3 true DK1603573T3 (da) 2008-09-15

Family

ID=32870338

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04709596T DK1603573T3 (da) 2003-02-13 2004-02-10 Anvendelse af dipyridamol i kombination med acetylsalicylsyre og en angiotensin II-antagonist til forebyggelse af slagtilfælde

Country Status (29)

Country Link
US (5) US20040214802A1 (de)
EP (2) EP1733729A1 (de)
JP (1) JP2006517557A (de)
KR (1) KR20050100676A (de)
CN (1) CN1750830A (de)
AR (1) AR043173A1 (de)
AT (1) ATE395921T1 (de)
AU (1) AU2004212305A1 (de)
BR (1) BRPI0407457A (de)
CA (1) CA2515941A1 (de)
DE (2) DE10306179A1 (de)
DK (1) DK1603573T3 (de)
EA (1) EA200501231A1 (de)
EC (1) ECSP055963A (de)
ES (1) ES2308147T3 (de)
HR (1) HRP20050713A2 (de)
MX (1) MXPA05008572A (de)
NO (1) NO20054216L (de)
NZ (1) NZ542302A (de)
PE (1) PE20050191A1 (de)
PL (1) PL378204A1 (de)
PT (1) PT1603573E (de)
RS (1) RS20050618A (de)
SI (1) SI1603573T1 (de)
TW (1) TW200501957A (de)
UA (1) UA83481C2 (de)
UY (1) UY28182A1 (de)
WO (1) WO2004071385A2 (de)
ZA (1) ZA200505956B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
CA2437709A1 (en) * 2003-08-08 2005-02-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of dipyridamole, acetylsalicylic acid and an angiotensin ii antagonist for treatment and prevention of vascular events
JP2005060359A (ja) * 2003-08-13 2005-03-10 Boehringer Ingelheim Pharma Gmbh & Co Kg 血管系病態の治療及び予防のためのジピリダモール、アセチルサリチル酸及びアンギオテンシンｉｉ拮抗薬の使用
WO2009080301A1 (en) * 2007-12-21 2009-07-02 Boehringer Ingelheim International Gmbh Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
WO2009100534A1 (en) * 2008-02-14 2009-08-20 Kardiatech, Inc. Combination therapy to treat vascular disorders
US20100069326A1 (en) * 2008-02-14 2010-03-18 Wasimul Haque Combination Therapies to Treat Cardio- and Cerebro-Vascular Disorders
WO2010097501A2 (en) * 2009-02-26 2010-09-02 Orion Corporation A combination treatment
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
TWI725008B (zh) * 2015-01-28 2021-04-21 瑞采生技有限公司 用於增強ＰＰＡＲγ表現及核轉位之化合物及其醫療用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031458A (en) * 1958-02-05 1962-04-24 Ciba Pharm Prod Inc Isoindolines
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
US3317279A (en) * 1963-03-15 1967-05-02 Pennsalt Chemicals Corp Polymorph of calcium disilicide and its method of preparation
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
US4318477A (en) * 1980-09-22 1982-03-09 Kerpe Stase Z Pharmaceutical package
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE3627423A1 (de) 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
EP1013273A1 (de) 1998-12-23 2000-06-28 Novartis AG Verwendung von AT-1 Rezeptorantagonisten oder AT-2 Rezeptormodulatoren zur Behandlung von Erkrankungen, die mit einer Erhöhung an AT-1 oder AT-2 Rezeptoren verbunden sind
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
EP1093814A1 (de) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Verwendung von Dipyridamole oder Mopidamol zur Herstellung eines Medikaments für die Behandlung und Vorbeugung von fibrinabhängigen Mikrozirkulationstörungen
JP2002138054A (ja) * 2000-08-25 2002-05-14 Takeda Chem Ind Ltd フィブリノーゲン低下剤
JP2002293742A (ja) * 2001-01-29 2002-10-09 Takeda Chem Ind Ltd 鎮痛・抗炎症剤
JP2003212758A (ja) * 2001-03-16 2003-07-30 Takeda Chem Ind Ltd 徐放性製剤の製造法
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe

Also Published As

Publication number Publication date
WO2004071385A3 (en) 2005-01-06
MXPA05008572A (es) 2005-11-04
US20080113949A1 (en) 2008-05-15
EP1733729A1 (de) 2006-12-20
ATE395921T1 (de) 2008-06-15
RS20050618A (en) 2007-09-21
HRP20050713A2 (en) 2006-09-30
US20080188497A1 (en) 2008-08-07
AR043173A1 (es) 2005-07-20
AU2004212305A1 (en) 2004-08-26
TW200501957A (en) 2005-01-16
US20040214802A1 (en) 2004-10-28
CA2515941A1 (en) 2004-08-26
PL378204A1 (pl) 2006-03-20
ECSP055963A (es) 2006-01-16
WO2004071385A2 (en) 2004-08-26
NO20054216D0 (no) 2005-09-12
EP1603573B8 (de) 2009-04-01
UA83481C2 (uk) 2008-07-25
PT1603573E (pt) 2008-06-26
ZA200505956B (en) 2006-03-29
DE602004013937D1 (de) 2008-07-03
CN1750830A (zh) 2006-03-22
NZ542302A (en) 2008-12-24
KR20050100676A (ko) 2005-10-19
SI1603573T1 (sl) 2008-10-31
UY28182A1 (es) 2004-09-30
NO20054216L (no) 2005-09-12
JP2006517557A (ja) 2006-07-27
EP1603573B1 (de) 2008-05-21
ES2308147T3 (es) 2008-12-01
EA200501231A1 (ru) 2006-02-24
DE10306179A1 (de) 2004-08-26
US20060241089A1 (en) 2006-10-26
EP1603573A2 (de) 2005-12-14
US20070004687A1 (en) 2007-01-04
PE20050191A1 (es) 2005-04-12
BRPI0407457A (pt) 2006-01-31

Similar Documents

Publication Publication Date Title
NO20054216D0 (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
DK1891973T3 (da) Kombinationer omfattende antimuskarine midler og PDE4-hæmmere
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
ATE435859T1 (de) Gyraseinhibitoren und deren verwendungen
DK1913157T3 (da) EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling
DK1531819T3 (da) Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen
DK3366283T3 (da) Direkte sammenpresningsformulering og fremgangsmåde
DK1597238T3 (da) HIV-replicationshæmmende pyrimidiner og triaziner
DK1583542T3 (da) Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
NO20054411D0 (no) Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse
DK1765793T3 (da) Anacetrapib og andre cetp-inhibitorer
NO20054969D0 (no) 2-cyanopropansyreamid- og esterderivater og deres anvendelse
HK1180218A1 (en) Methods and compositions involving mda-7 mda-7
ATE521604T1 (de) N-substituierte benzimidazolyl-c-kit-inhibitoren und kombinatorische benzimidazolbibliothek
IL177709A0 (en) Caspase inhibitors and uses thereof
FI20021144A0 (fi) Menetelmä suuntaajasiltojen yhteydessä
EP1586332A4 (de) Kombinierte verwendung voncarnosinas-inhibitor mit l-carnosinen und zusammensetzung
DK1829874T3 (da) Tricyklisk forbindelse og anvendelse deraf
DK1840121T3 (da) Glycinderivat og anvendelse heraf
DK1882054T3 (da) Korrosionsbeskyttelsesanordning og fremgangsmåde
IL178970A0 (en) Haplotype markers and methods of using the same to determine response to treatment
NO20044269L (no) Smamolekylaere inntrengningsinhibitorer
PL377427A1 (pl) Sposoby i kompozycje do leczenia infekcji wirusem opryszczki z zastosowaniem inhibitorów selektywnych względem cyklooksygenazy-2 lub inhibitorów cyklooksygenazy-2 w połączeniu ze środkami przeciwwirusowymi
ITRM20040058A1 (it) Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
ITPD20030078A1 (it) Dispositivo di collegamento e snodo per placchette di nasello